MedPath

Neovasc Inc.

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:1
Completed:2

Trial Phases

1 Phases

Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 2
2 (100.0%)

REDUCER-I: An Observational Study of the Neovasc Reducer™ System

Active, not recruiting
Conditions
Chronic Stable Angina
Angina Pectoris
Angina Pectoris, Stable
First Posted Date
2016-03-16
Last Posted Date
2025-01-01
Lead Sponsor
Neovasc Inc.
Target Recruit Count
400
Registration Number
NCT02710435
Locations
🇦🇹

University of Graz, Graz, Austria

🇧🇪

ZNA Middelheim Hospital, Antwerpen, Belgium

🇧🇪

Zienkenhuis Oost-Limburg, Genk, Belgium

and more 22 locations

Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA

Phase 2
Completed
Conditions
Refractory Angina
First Posted Date
2010-09-21
Last Posted Date
2013-11-25
Lead Sponsor
Neovasc Inc.
Target Recruit Count
104
Registration Number
NCT01205893
Locations
🇧🇪

ZNA Middelheim Hospital, Antwerpen, Belgium

🇧🇪

Ziekenhuis Oost-Limburg, Genk, Belgium

🇨🇦

Ottawa Heart Institute, Ottawa, Ontario, Canada

and more 8 locations

Evaluation of the Metricath Gemini System, a Device Intended to Make Arterial Measurements and Perform Angioplasty Dilations.

Phase 2
Completed
Conditions
Angioplasty
First Posted Date
2006-11-15
Last Posted Date
2009-05-13
Lead Sponsor
Neovasc Inc.
Target Recruit Count
145
Registration Number
NCT00399646
Locations
🇺🇸

UC Irvine Medical Center, Orange, California, United States

🇺🇸

Mercy Heart Institute, Sacramento, California, United States

🇺🇸

Pasco Cardiology Center, Hudson, Florida, United States

and more 13 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.